Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 72Neoplasms 64Prostatic Neoplasms 45Colorectal Neoplasms 42Lung Neoplasms 38Carcinoma, Non-Small-Cell Lung 26Pancreatic Neoplasms 21Neoplasm Metastasis 20Hematologic Neoplasms 20Head and Neck Neoplasms 20Urinary Bladder Neoplasms 15Ovarian Neoplasms 14Multiple Myeloma 11Motor Activity 11Leukemia, Myeloid, Acute 11Stomach Neoplasms 10Squamous Cell Carcinoma of Head and Neck 10Uterine Cervical Neoplasms 9Triple Negative Breast Neoplasms 9Glioblastoma 9Colonic Neoplasms 9Hematopoietic and Lymphatic System Neoplasm 8Glioma 8Gastrointestinal Neoplasms 8Carcinoma, Renal Cell 8COVID-19 8Anxiety Disorders 8Anatomic Stage I Breast Cancer AJCC v8 8Rectal Neoplasms 7Melanoma 7

Interventions

enzalutamide 6Abiraterone Acetate 6olaparib 5Docetaxel 5darolutamide 4Prednisone 4Pluvicto 4cabazitaxel 3testosterone 17 beta-cypionate 2radium Ra 223 dichloride 2fludarabine 2abiraterone 2Prednisolone 2Nivolumab 2Cyclophosphamide 2Androgen Antagonists 2sipuleucel-T 1rucaparib 1poly ICLC 1pamiparib 1lactitol 1fludarabine phosphate 1fluciclovine F-18 1enfortumab vedotin 1ebastine 1copanlisib 1cabozantinib 1bempegaldesleukin 1avelumab 1alovudine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Metastatic Castration-resistant Prostate Cancer × Standard of Care × Clear all
NCT06401980 2026-03-30

Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Swiss Cancer Institute

Phase 2 Recruiting
162 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡